Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases - PubMed

Review

Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases

Sebastian Zundler et al. Inflamm Bowel Dis. 2017 Apr.

Abstract

Therapeutic compounds interfering with T cell trafficking are a new column of inflammatory bowel disease (IBD) treatment. Currently, the anti-α4β7 integrin antibody vedolizumab is successfully used in the clinic and further drugs are likely to follow. Despite these clinical advances, the precise mechanistic background of their action is only gradually elucidated and still a matter of intensive research. Only recently, advances made with the help of new in vivo models and human studies have contributed to shape our concept of T cell trafficking in IBD by deciphering some important and so far unanswered questions. At the same time, basic and clinical data have generated new issues to be addressed on the way toward a clear perception of trafficking mechanisms and toward elucidation of the action of compounds interfering with this process. In this review, we will give a comprehensive outline of all components of T cell trafficking in regard to IBD before discussing the current knowledge concerning targeted interference with integrins in this complex network. Moreover, we will summarize remaining ambiguity and give an outlook on potential future targets.

Similar articles

• Blockade of αEβ7 integrin suppresses accumulation of CD8⁺ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo.

  Zundler S, Schillinger D, Fischer A, Atreya R, López-Posadas R, Watson A, Neufert C, Atreya I, Neurath MF. Zundler S, et al. Gut. 2017 Nov;66(11):1936-1948. doi: 10.1136/gutjnl-2016-312439. Epub 2016 Aug 19. Gut. 2017. PMID: 27543429

• Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances.

  Zundler S, Becker E, Schulze LL, Neurath MF. Zundler S, et al. Gut. 2019 Sep;68(9):1688-1700. doi: 10.1136/gutjnl-2018-317977. Epub 2019 May 24. Gut. 2019. PMID: 31127023 Review.

• Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing.

  Schleier L, Wiendl M, Heidbreder K, Binder MT, Atreya R, Rath T, Becker E, Schulz-Kuhnt A, Stahl A, Schulze LL, Ullrich K, Merz SF, Bornemann L, Gunzer M, Watson AJM, Neufert C, Atreya I, Neurath MF, Zundler S. Schleier L, et al. Gut. 2020 Feb;69(2):252-263. doi: 10.1136/gutjnl-2018-316772. Epub 2019 May 15. Gut. 2020. PMID: 31092589

• Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.

  Zeissig S, Rosati E, Dowds CM, Aden K, Bethge J, Schulte B, Pan WH, Mishra N, Zuhayra M, Marx M, Paulsen M, Strigli A, Conrad C, Schuldt D, Sinha A, Ebsen H, Kornell SC, Nikolaus S, Arlt A, Kabelitz D, Ellrichmann M, Lützen U, Rosenstiel PC, Franke A, Schreiber S. Zeissig S, et al. Gut. 2019 Jan;68(1):25-39. doi: 10.1136/gutjnl-2018-316023. Epub 2018 May 5. Gut. 2019. PMID: 29730603

• Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.

  Lamb CA, O'Byrne S, Keir ME, Butcher EC. Lamb CA, et al. J Crohns Colitis. 2018 Aug 22;12(suppl_2):S653-S668. doi: 10.1093/ecco-jcc/jjy060. J Crohns Colitis. 2018. PMID: 29767705 Review.

Cited by

• Mutual Regulation of TLR/NLR and CEACAM1 in the Intestinal Microvasculature: Implications for IBD Pathogenesis and Therapy.

  Schirbel A, Rebert N, Sadler T, West G, Rieder F, Wagener C, Horst A, Sturm A, de la Motte C, Fiocchi C. Schirbel A, et al. Inflamm Bowel Dis. 2019 Jan 10;25(2):294-305. doi: 10.1093/ibd/izy316. Inflamm Bowel Dis. 2019. PMID: 30295747 Free PMC article.

• Intestinal Mucosal Wound Healing and Barrier Integrity in IBD-Crosstalk and Trafficking of Cellular Players.

  Sommer K, Wiendl M, Müller TM, Heidbreder K, Voskens C, Neurath MF, Zundler S. Sommer K, et al. Front Med (Lausanne). 2021 Mar 23;8:643973. doi: 10.3389/fmed.2021.643973. eCollection 2021. Front Med (Lausanne). 2021. PMID: 33834033 Free PMC article. Review.

• Impact of Bacterial Metabolites on Gut Barrier Function and Host Immunity: A Focus on Bacterial Metabolism and Its Relevance for Intestinal Inflammation.

  Gasaly N, de Vos P, Hermoso MA. Gasaly N, et al. Front Immunol. 2021 May 26;12:658354. doi: 10.3389/fimmu.2021.658354. eCollection 2021. Front Immunol. 2021. PMID: 34122415 Free PMC article. Review.

• Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases.

  Marafini I, Monteleone G. Marafini I, et al. Biologics. 2020 Jun 15;14:47-51. doi: 10.2147/BTT.S257638. eCollection 2020. Biologics. 2020. PMID: 32606588 Free PMC article. Review.

• The Resolution of Intestinal Inflammation: The Peace-Keeper's Perspective.

  Onali S, Favale A, Fantini MC. Onali S, et al. Cells. 2019 Apr 11;8(4):344. doi: 10.3390/cells8040344. Cells. 2019. PMID: 30979024 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • scite Smart Citations